EMA Recommends Granting a Marketing Authorisation for Darolutamide
It is recommended for the treatment of non-metastatic castration resistant prostate cancer at high risk of developing metastatic disease
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
PIK3CA-mutated Metastatic Breast Cancer
An analysis from SAFIR02 trial results in better understanding of the characteristics of the MBC population harbouring PIK3CA mutations
EMA Suspends Ingenol Mebutate as a Precaution While Review of Skin Cancer Risk Continues
Higher incidence of skin malignancy with ingenol mebutate than with imiquimod
Cancer Related to Infections
An analysis of GLOBOCAN 2018 database points to a need for resources directed towards cancer prevention programmes that target infection
FDA Grants Accelerated Approval to Tazemetostat
It is indicated for metastatic or locally advanced epithelioid sarcoma
Ten Recommendations for Best Use of Big Data to Support Public Health in the EU
Priority recommendations of the HMA-EMA joint Big Data Task Force
ESMO Releases New Patient Guide in Biliary Tract Cancer
A comprehensive new edition presents the latest information in cholangiocarcinoma, gallbladder cancer and ampullary cancer
Frequency, Mutational Patterns, and Genomic Profile of Hypermutated Breast Cancer
High tumour mutational burden more common in metastatic tumours
Immune Checkpoint Inhibitors Associated with Lower Risk of Developing Severe and Any Adverse Events Compared to Chemotherapy
Results from the largest and most comprehensive meta-analysis across multiple primary solid tumours
Crizotinib in NSCLC With a MET Exon 14 Alteration
Addressing an unmet need for targeted therapy in lung cancers
EMA Recommends Granting Marketing Authorisation for Azacitidine Accord
It is a generic of Vidaza, which has been authorised in the EU since December 2008
FDA Approves Avapritinib for GIST with a PDGFRA Exon 18 Mutation
Efficacy was evaluated in NAVIGATOR trial